HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

430.463

+8.7162.07%

Number of Gainers:27

Number of Losers:4

Number of Flat:3

PE:- -

High:431.911

Open:421.747

Low:421.747

Close:421.747

Loading ...

Immunotech Biopharm Ltd (HKG:6978) Top Key Executive Zheng Tan, the company's largest shareholder sees 15%reduction in holdings value

Simply Wall St.

BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Olverembatinib Granted Breakthrough Therapy Designation for Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All)

THOMSON REUTERS

Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%

MT Newswires Live

BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio

Alphamab Oncology to Turn to 2024 Profit

MT Newswires Live

Retail investors are Ascentage Pharma Group International's (HKG:6855) biggest owners and were hit after market cap dropped HK$720m

Simply Wall St.

Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio

THOMSON REUTERS

BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit

BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For Year

Alphamab Oncology - Expected Result Due to Three License Collaborations and Sales Revenue in FY

THOMSON REUTERS

Alphamab Oncology Sees Profit of Not Less Than RMB150.0 Mln for Year

THOMSON REUTERS

CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial

MT Newswires Live

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody

THOMSON REUTERS

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.

CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":430.4633,"timestamp":1741248510375,"preClose":421.74713,"halted":0,"volume":196751826,"delay":0,"changeRate":0.020667,"change":8.716156,"pbRate":3.352817,"amount":2078205803,"amplitude":0.024099,"prevYearClose":331.1933,"fiveDayClose":431.446,"twentyDayClose":333.662,"turnoverRate":0.00762,"marketCap":241153069920,"floatMarketCap":226975358368,"peRate":-16.712341},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":431.91098,"amplitude":0.024099,"preClose":421.74713,"low":421.74713,"pbRate":"3.352817","latestPrice":430.4633,"volume":196751826,"delay":0,"open":421.74713,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":431.446,"twentyDayClose":333.662,"sixtyDayClose":346.493,"secType":"PLATE","market":"HK","turnoverRate":0.00762,"peRate":-16.712341,"marketCap":241153069920,"floatMarketCap":226975358368,"timestamp":1741248510375,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":27,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517213101","title":"Immunotech Biopharm Ltd (HKG:6978) Top Key Executive Zheng Tan, the company's largest shareholder sees 15%reduction in holdings value","url":"https://stock-news.laohu8.com/highlight/detail?id=2517213101","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517213101?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:09","pubTimestamp":1741216185,"startTime":"0","endTime":"0","summary":"Key Insights Insiders appear to have a vested interest in Immunotech Biopharm's growth, as seen by their sizeable...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6978/immunotech-biopharm-shares/news/immunotech-biopharm-ltd-hkg6978-top-key-executive-zheng-tan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2517978453","title":"BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978453","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978453?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:03","pubTimestamp":1741215813,"startTime":"0","endTime":"0","summary":"BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)March 5 (Reuters) - Ascentage Pharma Group I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"2517978965","title":"Olverembatinib Granted Breakthrough Therapy Designation for Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978965?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:01","pubTimestamp":1741215701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2517697559","title":"Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697559","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517697559?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:39","pubTimestamp":1741160361,"startTime":"0","endTime":"0","summary":"Antengene  obtained new drug application approval for three indications of XPOVIO  from the Indonesia National Agency of Drug and Food Control, a Wednesday Hong Kong bourse filing said.The indications include a combination with bortezomib and dexamethasone used for the treatment of multiple myeloma in adult patients, a combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, and as a monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients.Multiple myeloma is a cancer related to the white blood cells called plasma cells, while diffuse large B-cell lymphoma is cancer related to the white blood cells called lymphocytes.Shares of the company were up nearly 11% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06996","BK1583","BK1191"],"gpt_icon":0},{"id":"2517969313","title":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517969313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517969313?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:28","pubTimestamp":1741159699,"startTime":"0","endTime":"0","summary":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For XpovioMarch 5  - Antengene Corp Ltd 6996.HK:APPROVAL OF NDA BY INDONESIA NATIONAL AGENCY OF DRUG AND FOOD CONTROL FOR XPOVIOFurther company coverage: 6996.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1191","06996"],"gpt_icon":0},{"id":"2517963731","title":"Alphamab Oncology to Turn to 2024 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517963731","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517963731?lang=en_us&edition=fundamental","pubTime":"2025-03-05 14:52","pubTimestamp":1741157539,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  expects a profit of at least 150 million yuan for the year 2024, compared with a loss of around 210.6 million yuan a year prior, a Tuesday filing with the Hong Kong bourse said.The drugmaker attributed the anticipated turnaround to profit mainly to three license collaborations and sales revenue.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2517911944","title":"Retail investors are Ascentage Pharma Group International's (HKG:6855) biggest owners and were hit after market cap dropped HK$720m","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911944","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911944?lang=en_us&edition=fundamental","pubTime":"2025-03-05 14:15","pubTimestamp":1741155303,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in Ascentage Pharma Group International indicates that they...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/retail-investors-are-ascentage-pharma-group-internationals-h-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2517195939","title":"Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:00","pubTimestamp":1741147235,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06996","BK1583","BK1574","BK1191"],"gpt_icon":0},{"id":"2517956763","title":"BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517956763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517956763?lang=en_us&edition=fundamental","pubTime":"2025-03-05 11:58","pubTimestamp":1741147114,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit  ** Shares of Alphamab Oncology 9966.HK jump as much as 15.8% to HK$6.07, set for biggest one-day pct gain since February 27** Stock top pct gainer on healthcare index .HSCIH, which is up 1.1%** The oncology drugs developer expects to record a net profit of 150 mln yuan  for 2024 as compared to a loss of 210.6 mln yuan in 2023; this is the first time the company expects to achieve an annual profit** The Hang Seng Commerce & Industry Index .HSNC jumps 1.9%, Hang Seng Index .HSI rises 1.6%** Stock up 73.4% YTD    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL2N3PO06W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2516672802","title":"BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516672802?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:29","pubTimestamp":1741098563,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For YearMarch 4  - Alphamab Oncology 9966.HK:SEES PROFIT OF NOT LESS THAN RMB150.0 MILLION FOR YEAREXPECTED RESULT DUE TO THREE LICENSE COLLABORATIONS AND SALES REVENUE IN FYFurther company coverage: 9966.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2516620764","title":"Alphamab Oncology - Expected Result Due to Three License Collaborations and Sales Revenue in FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620764?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:06","pubTimestamp":1741089999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2516207616","title":"Alphamab Oncology Sees  Profit of Not Less Than RMB150.0 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2516207616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516207616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:06","pubTimestamp":1741089999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2516144536","title":"CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516144536","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516144536?lang=en_us&edition=fundamental","pubTime":"2025-03-04 13:43","pubTimestamp":1741067010,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  said the first patient was successfully dosed in the global multicenter Phase I clinical trial of its independently developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, without infusion reactions or other adverse events, according to a Tuesday filing with the Hong Kong Stock Exchange.CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4 to boost the immune response against tumors. It is designed to reinvigorate exhausted immune cells while neutralizing VEGF, making it a potential breakthrough for various cancers, including lung, liver, and ovarian cancer, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2516608698","title":"CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608698?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA2RYCFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2516708635","title":"Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516708635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516708635?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:06","pubTimestamp":1740974772,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Everest Medicines by retail investors implies that the general public has more...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limiteds-hkg1952-biggest-owners-are-retail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01952","MDCO","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2516930525","title":"CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2516930525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516930525?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:15","pubTimestamp":1740960905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUANP7GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1585","BK1587","02171","BK1161"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":57}]}}